Malignant pleural mesothelioma (MPM) is a rare neoplasm, generally caused by asbestos exposure. This case details how a patient treated with nintedanib during the LUME-Meso study was rechallenged with nintedanib. The findings highlight the benefit of nintedanib rechallenge and the potential use of continuous anti-angiogenic therapy in MPM treatment.
No takes yet. Share an insight, caveat, or question.
Grosso et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: